Hims & Hers Health, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a HIMS research report →
Range $21 – $40
Price Chart
About the company
Hims & Hers Health, Inc. operates a comprehensive digital health platform that seamlessly links individuals with licensed medical professionals for virtual consultations and ongoing care. Through its user-friendly websites and mobile app, the company delivers a diverse portfolio of health and wellness solutions directly to consumers.
- CEO
- Andrew Dudum
- IPO
- 2019
- Employees
- 2,442
- HQ
- San Francisco, CA, US
AI snapshot
Six angles, distilled from the data.
HIMS is in a deep corrective regime after a long run-up, still trading well below its 200-day average and far under the 52-week high. The stock has already reset from peak levels, so the setup is more about whether it can stabilize near the lower end of its yearly range than about momentum continuation.
Street sentiment is cautious but not bearish: consensus sits at Hold with a $31 target, well above the current share price. Recent action has been mostly target cuts and reiterated neutral-to-positive views, with KeyBanc, UBS, and Needham all holding their prior stances while trimming expectations.
The earnings profile is mixed: HIMS has beaten 3 of the last 7 quarters, but the most recent report missed by 57.1%. Next-year EPS is still modeled negative at -0.0653, so shareholders should watch whether revenue growth can keep outrunning margin pressure and whether the company can re-accelerate earnings quality.
Recent insider activity leans negative on discretionary trades, led by multiple sales from the CFO and Chief Legal Officer. Several large award and exempt transactions also hit the tape, but those are compensation-related noise; the signal is the cluster of open-market selling rather than buying.
The business still grows fast, with revenue up 48.6% year over year, but profitability remains under pressure. Gross margin is 64.8%, while operating margin is -6.39% and net margin is -6.65%; the balance sheet carries $1.12 billion of debt against $577.5 million of cash, leaving net debt.
HIMS stands out for growth and gross margin, but it still trails more mature healthcare peers on earnings consistency and balance-sheet flexibility. At a negative trailing P/E and a market cap near $4.1 billion, the valuation is tied more to execution and margin recovery than to current earnings power.
Similar companies
Peers in the same neighborhood.
- Market Cap
- $3.30B
- P/E
- -18.02
- Fwd P/E
- 75.06
- PEG
- 0.41
- P/S
- 1.16
- P/B
- 9.72
- EV/EBITDA
- -37.56
- Div Yield
- 0.00%
- Gross Margin
- 60.45%
- Op Margin
- -5.95%
- Net Margin
- -6.65%
- ROE
- -45.81%
- ROIC
- -6.91%
Latest fiscal year · YoY change
- Revenue
- $2.35B+59.0%
- Gross Profit
- $1.73B+47.8%
- Op Income
- $105.61M
- Net Income
- $128.37M+1.8%
- EPS
- $0.57-1.7%
- OCF Growth
- +19.5%
- FCF Growth
- -62.7%
- 52W High
- $40.99
- 52W Low
- $13.74
- 50D MA
- $26.77
- 200D MA
- $26.51
- Beta
- 2.50
- RSI (14)
- 25
- Avg Volume
- 11.93M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Hims & Hers posted 49% revenue growth and raised its full-year revenue outlook, but is intentionally trading near-term subscriber growth and margins for broader assortment, international expansion, and new platform capabilities.· November 9, 2026
- Revenue rose 49% year over year to $890 million, the second straight quarter of accelerating growth.
- Subscribers grew 13% year over year to 2.8 million, but fell 100,000 sequentially as marketing was pulled back and international brands were migrated.
- Gross margin was 57%, down about 7 points sequentially, mainly because of lower-margin branded weight-loss mix in international markets.
- Adjusted EBITDA was $82 million, or a 9% margin; free cash flow was $26 million and cash/investments topped $710 million.
- Management raised 2026 revenue guidance to $3.13 billion-$3.15 billion and said international revenue should reach at least $650 million in 2026.
Third-quarter revenue grew 49% year over year to $890 million; revenue excluded $18 million from deferred weight-loss membership revenue that will be recognized in the fourth quarter. Subscribers increased 13% year over year to 2.8 million, while adjusted EBITDA rose 37% quarter over quarter to $82 million, equal to a 9% margin. GAAP net income was a loss of $33 million, gross margin was 57% (down about 7 points sequentially), cash from operations was $65 million, and free cash flow was $26 million. For the fourth quarter, management guided to revenue of $875 million to $895 million and adjusted EBITDA of $70 million to $90 million. For full-year 2026, revenue guidance was tightened to $3.13 billion to $3.15 billion, adjusted EBITDA guidance was reduced to $257 million to $277 million, and management said it expects positive free cash flow for the full year.
Andrew Dudum framed the quarter as proof of a long-term platform strategy centered on owning the customer relationship, not just selling a treatment. He emphasized a broader health platform across metabolic care, international markets, and new categories like TRT and peptides, backed by more than 1 million square feet of pharmacy, lab, and compounding infrastructure. His tone was confident and strategic, but he repeatedly acknowledged the company is deliberately sacrificing some near-term growth to set up stronger economics and product breadth into 2027.
Yemi Okupe focused on the tradeoff between near-term volatility and longer-term operating leverage. He highlighted 49% revenue growth to $890 million, 57% gross margin, $82 million of adjusted EBITDA, $26 million of free cash flow, and over $710 million of cash and investments. He said marketing was 28% of revenue, support costs were 12%, and G&A improved to 17%, while noting the 2026 EBITDA guide was cut because of more aggressive international pricing/marketing and the weight-loss membership revenue deferral. He also said the company expects at least $650 million of international revenue in 2026 and still expects positive free cash flow for the year.
Analysts focused on the subscriber decline, the rationale for pulling back on marketing, the impact of adding Lilly alongside Novo in weight loss, the peptide launch timeline, and how AI will improve both consumer experience and internal efficiency. Management said the subscriber decline was mainly deliberate underinvestment in domestic weight loss and international brand migrations, and that growth should recover as the company broadens assortment and re-accelerates marketing into the seasonally stronger first quarter. On peptides, Andrew Dudum said Peptides+ is expected later this month, the company has strong wait-list interest, and it intends to manufacture certain raw APIs in-house in Menlo Park while waiting for final regulatory clarity. On AI, management said the new experience is driving higher engagement, faster response times, and more efficient provider workflows.
The bull case from this call is that Hims & Hers is still growing quickly while expanding into a broader, more defensible platform. Management sees weight loss, international markets, AI-enabled care, and new categories like TRT and peptides as multiple growth engines that can reinforce one another. They also pointed to strong cash generation and a large cash balance, suggesting they can keep investing while still producing free cash flow.
The main risks are near-term volatility, lower margins, and sequential subscriber declines from intentional marketing pullbacks and international brand changes. Management also acknowledged that branded weight-loss mix and international expansion are pressuring gross margin, and that full-year EBITDA guidance was reduced because of pricing and marketing actions. Peptide revenue is not expected to be material in the fourth quarter, and the company is still awaiting regulatory clarity on parts of that opportunity.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 94.2%
- Shares Outstanding
- 226.03M
- Float Shares
- 212.92M
of shares held by institutions
587 13F filers
Buy/sell ratio 0.35. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for HIMS, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Lisa C. McClainHouse · MI09 | Buy | Aug 4, 25 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 29.74M | ▲ 1.04M |
| Vanguard Group Inc | 20.93M | ▲ 1.41M |
| Vanguard Portfolio Management LLC | 10.41M | ▼ 150.18K |
| Vanguard Capital Management LLC | 9.53M | ▼ 14.98K |
| State Street Corp | 8.24M | ▲ 94.26K |
| Divisadero Street Capital Management, LP | 7.34M | ▲ 1.33M |
| Morgan Stanley | 6.24M | ▼ 913.48K |
| Geode Capital Management, LLC | 5.63M | ▼ 51.27K |
| Ubs Group AG | 4.75M | ▲ 2.09M |
| Jpmorgan Chase & Co | 4.75M | ▼ 14.43K |
| Fmr LLC | 4.68M | ▲ 352.08K |
| Two Sigma Investments, LP | 4.37M | ▲ 4.37M |
Held by 428 ETFs
Biggest fund positions in HIMS by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 17, 26 | Okupe Oluyemi | sell | 3,518 |
| Nov 17, 26 | Autor Deborah M. | sell | 23,828 |
| Nov 17, 26 | Boughton Soleil | sell | 3,458 |
| Nov 13, 26 | Payne Christopher D | other | 810 |
| Nov 13, 26 | Payne Christopher D | other | 810 |
| Nov 13, 26 | Boughton Soleil | other | 42,262 |
| Nov 13, 26 | Boughton Soleil | other | 21,500 |
| Nov 13, 26 | Boughton Soleil | other | 11,757 |
| Nov 13, 26 | Boughton Soleil | other | 12,099 |
| Nov 13, 26 | Boughton Soleil | other | 6,183 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our HIMS coverage
Recent articles, reports, and earnings notes.

Hims & Hers Health (HIMS): Growth Is Real, But Execution Matters
Hims & Hers is scaling fast, with Q2 revenue up 38% and subscribers up 19%, but profitability, leverage, and regulatory risk keep the story from being a simple growth call. The stock still earns a Buy, though investors need to watch cash flow and margin pressure closely.

Hims & Hers Health, Inc. (HIMS) falls on deep earnings miss
Hims & Hers Health, Inc. (HIMS) falls after a Q3 miss that went beyond the headline. This deep-dive examines weaker margins, softer guidance, shifting product mix, and the growth-versus-profit tradeoff behind the stock’s decline.

Hims & Hers Health, Inc. (HIMS) falls on earnings misses
Hims & Hers Health, Inc. (HIMS) falls after reporting earnings misses, sending shares lower as investors react to weaker-than-expected results and outlook concerns.
Want a deeper read on HIMS?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Hims & Hers Launches Peptides+ to Expand Personalized Health Care
zacks.com · Nov 20
Hims & Hers launches new peptide treatments — while admitting there's more to learn about efficacy
cnbc.com · Nov 18
Hims & Hers Launches Peptides+, a New Clinically-Guided Specialty for Access to Personalized, Proactive Health
businesswire.com · Nov 18
Hims & Hers: Further Expanding Internationally
seekingalpha.com · Nov 16
Hims & Hers Health Stock Crashes After Earnings: Is Now the Time to Buy?
fool.com · Nov 16
Why Is Hims Stock Crashing, and is it a Buying Opportunity?
fool.com · Nov 14
Hims & Hers Health, Inc. $HIMS Shares Sold by Commonwealth Equity Services LLC
defenseworld.net · Nov 14
Hims & Hers Stock Just Plummeted 17%. Is the Stock a Buy Ahead of a Peptide Push?
fool.com · Nov 13
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
AI analysis · Last refreshed November 17, 2026 · Live quote · Not investment advice